Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patient preferences for interferon alfa in multiple myeloma

H Ludwig1, E Fritz, J Neuda

  • 11st Department of Medicine and Oncology, Wilhelminenspital, Vienna, Austria. 1melud@wil.magwien.gv.at

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 1, 1997
PubMed
Summary

Patient preferences for interferon alfa treatment in multiple myeloma indicate that about half accept it for a 6-month survival gain. Gaining 12 months survival increases acceptance among those initially refusing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic Aspects of the Hematologic Neoplasms.

Postgraduate medicine·2016
Same author

[(14)C-Microautoradiography of water-soluble substances in the phloem].

Planta·2014
Same author

Microautoradiographic investigations on bidirectional translocation in the phloem of Vicia faba.

Planta·2014
Same author

The influence of light, darkness, and lack of CO2 on phloem translocation in detached maize leaves.

Planta·2014
Same author

The influence of externally supplied sucrose on phloem transport in the maize leaf strip.

Planta·2014
Same author

Microautoradiographic studies of phloem loading and transport in the leaf of Zea mays L.

Planta·2013

Area of Science:

  • Oncology
  • Hematology
  • Pharmacoeconomics

Background:

  • Interferon alfa offers marginal survival benefits in multiple myeloma but incurs toxicity and cost.
  • Understanding patient preferences is crucial for shared decision-making, especially when patients cannot actively participate.
  • Physician guidance requires knowledge of patient values regarding treatment outcomes and side effects.

Purpose of the Study:

  • To ascertain patient preferences for interferon alfa treatment in multiple myeloma.
  • To gather data facilitating medical decision-making by understanding patient values.
  • To inform clinical practice regarding the acceptability of interferon alfa therapy.

Main Methods:

  • Telephone interviews with 355 multiple myeloma patients across the United States.

Related Experiment Videos

  • Presentation of potential benefits (remission rate, duration, survival gains) and risks (toxicity, cost, self-injection) of an unidentified treatment.
  • Multivariate regression analysis to identify characteristics of patients accepting or rejecting the treatment.

    • Main Results:

    • Approximately 50% of patients accepted the unidentified treatment if it offered at least a 6-month gain in remission or overall survival.
    • Patients who accepted were younger and more likely to have prior interferon exposure.
    • 25-50% of patients who initially rejected the treatment would accept it if benefits increased to 12 months.

    Conclusions:

    • Interferon therapy, and similar treatments, are acceptable to about half of multiple myeloma patients when a 6-month survival benefit is anticipated.
    • Patient acceptance is dose-dependent on the magnitude of survival gains.
    • Patient preferences significantly influence the perceived value of cancer treatments.